Department of Anaesthesia, Orthopaedic Hospital Orton, Invalid Foundation, Helsinki, Finland.
Acta Anaesthesiol Scand. 2011 Mar;55(3):273-81. doi: 10.1111/j.1399-6576.2010.02325.x. Epub 2010 Oct 7.
Chloroprocaine and articaine have recently gained interest as short-acting spinal anaesthetics. They have not, however, previously been compared in an ambulatory surgery setting.
In this double-blind, randomised, controlled trial, adult patients (≤65 years, ASA I-II, body mass index<36 kg/m2) underwent day-case knee arthroscopy under spinal anaesthesia with either 40 mg of plain chloroprocaine (20 mg/ml) (group C40; n=39) or 60 mg of plain articaine (40 mg/ml) (group A60; n=39). Study parameters included the onset, degree, and regression of both sensory and motor block. Standardised telephone interviews on the first and seventh post-operative day were aimed at detecting any untoward sequelae, e.g., transient neurologic symptoms (TNSs).
The groups were comparable regarding demographic data, onset and maximal spread of spinal anaesthesia, and duration of surgery. All arthroscopies were performed successfully under spinal anaesthesia, except for one patient (C40, unforeseen delay in the start of surgery). The duration of sensory block≥dermatome L1 was significantly shorter in C40 vs. A60. Correspondingly, complete recovery was significantly faster (P<0.0001, Mann-Whitney U-test) in C40 vs. A60 for both motor [75 (60/90) vs. 135 (105/150) min] and sensory [105 (105/135) vs. 165 (135/180) min] block, respectively [data are median (25th/75th percentiles)]. No TNSs were noted.
Both anaesthetics used provided a rapid onset of spinal anaesthesia of about 1 h and were satisfactory for day-case knee arthroscopy. Recovery, however, was significantly faster in group C40. The data add to earlier results that TNSs seem to be uncommon after spinal chloroprocaine and articaine.
氯普鲁卡因和阿替卡因最近作为短效椎管内麻醉剂引起了关注。然而,它们以前并没有在日间手术环境中进行比较。
在这项双盲、随机、对照试验中,成年患者(≤65 岁,ASA I-II,体重指数<36 kg/m2)在椎管内麻醉下接受膝关节镜检查,使用 40 mg 普通氯普鲁卡因(20 mg/ml)(C40 组;n=39)或 60 mg 普通阿替卡因(40 mg/ml)(A60 组;n=39)。研究参数包括感觉和运动阻滞的起始、程度和消退。术后第 1 天和第 7 天进行标准化电话访谈,旨在检测任何不良后果,例如短暂性神经症状(TNSs)。
两组在人口统计学数据、椎管内麻醉的起始和最大扩散以及手术持续时间方面无差异。除一名患者(C40 组,手术开始时间意外延迟)外,所有膝关节镜检查均在椎管内麻醉下成功完成。C40 组感觉阻滞持续时间≥L1 皮节明显短于 A60 组。相应地,C40 组运动阻滞[75(60/90)min 对 135(105/150)min]和感觉阻滞[105(105/135)min 对 165(135/180)min]的完全恢复明显快于 A60 组(P<0.0001,Mann-Whitney U 检验)。两组均未出现 TNSs。
两种麻醉剂均能迅速起效,椎管内麻醉时间约为 1 小时,适用于日间膝关节镜检查。然而,C40 组的恢复明显更快。这些数据增加了早期的结果,即 TNSs 似乎在脊髓氯普鲁卡因和阿替卡因后并不常见。